# US 2017/0253633 A1 · Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253633 A1
- Document ID: US20170253633A1
- Status: Published application
- Kind: A1
- Application number: 15/445,461
- Filed: 2017-02-28
- Published: 2017-09-07
- Earliest claimed: 2016-03-01
- Assignees: Immatics Biotechnologies GmbH
- Applicants: Immatics Biotechnologies GmbH
- Inventors: Andrea MAHR; Toni WEINSCHENK; Colette SONG; Oliver SCHOOR; Jens FRITSCHE; Harpreet SINGH
- Web page: https://patentgrep.com/patent/US20170253633A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/0011: {Cancer antigens}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/18: against material from animals or humans
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- A61K 2039/80: {Vaccine for a specifically defined cancer}
- A61K 2039/804: {Blood cells [leukemia, lymphoma]}
- A61K 2039/812: {Breast}
- A61K 2039/82: {Colon}
- A61K 2039/828: {Stomach}
- A61K 2039/836: {Intestine}
- A61K 2039/844: {Liver}
- A61K 2039/852: {Pancreas}
- A61K 2039/86: {Lung}
- A61K 2039/868: {kidney}
- A61K 2039/876: {Skin, melanoma}
- A61K 2039/884: {prostate}
- A61K 2039/892: {Reproductive system [uterus, ovaries, cervix, testes]}
- C07K 2319/00: Fusion polypeptide
- C12N 2310/16: Aptamers
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

## Claims

### Claim 1

A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 149, and variant sequences thereof which are at least 88% homologous to SEQ ID No. 1 to SEQ ID No. 149, and wherein said variant binds to molecule(s) of the major histocompatibility complex (MHC) and/or induces T cells cross-reacting with said variant peptide; and a pharmaceutical acceptable salt thereof, wherein said peptide is not a full-length polypeptide.

### Claim 2 (depends on 1)

The peptide or variant according to claim 1, wherein said peptide has the ability to bind to an MHC class-I or -II molecule, and wherein said peptide, when bound to said MHC, is capable of being recognized by CD4 and/or CD8 T cells.

### Claim 3 (depends on 1)

The peptide or variant thereof according to claim 1, wherein the amino acid sequence thereof comprises a continuous stretch of amino acids according to any one of SEQ ID No. 1 to SEQ ID No. 149.

### Claim 4 (depends on 1)

The peptide or variant thereof according to claim 1, wherein said peptide or variant thereof has an overall length of from 8 to 100, optionally from 8 to 30, and optionally from 8 to 16 amino acids, and optionally wherein the peptide consists or consists essentially of an amino acid sequence according to any of SEQ ID No. 1 to SEQ ID No. 149.

### Claim 5

A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 149, and variant sequences thereof which are at least 88% homologous to SEQ ID No. 1 to SEQ ID No. 149, and wherein said variant binds to molecule(s) of the major histocompatibility complex (MHC) and/or induces T cells cross-reacting with said variant peptide; and a pharmaceutical acceptable salt thereof, wherein said peptide is not a full-length polypeptide, and wherein said peptide is modified and/or includes non-peptide bonds.

### Claim 6 (depends on 1)

The peptide or variant thereof according to claim 1, wherein said peptide is part of a fusion protein, optionally comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii).

### Claim 7 (depends on 1)

An antibody, optionally a soluble or membrane-bound antibody, optionally a monoclonal antibody or fragment thereof, that specifically recognizes the peptide or variant thereof according claim 1, optionally the peptide or variant thereof is bound to an MHC molecule.

### Claim 8 (depends on 1)

A T-cell receptor, optionally soluble or membrane-bound, or a fragment thereof, that is reactive with an HLA ligand, wherein said ligand is the peptide or variant thereof according to claim 1, optionally the peptide or variant thereof is bound to an MHC molecule.

### Claim 9 (depends on 8)

The T-cell receptor according to claim 8, wherein said ligand amino acid sequence is at least 88% identical to any one of SEQ ID No. 1 to SEQ ID No. 149, or wherein said ligand amino acid sequence consists of any one of SEQ ID No. 1 to SEQ ID No. 149.

### Claim 10 (depends on 8)

The T-cell receptor according to claim 8, wherein said T-cell receptor is provided as a soluble molecule and optionally carries a further effector function optionally an immune stimulating domain or toxin.

### Claim 11 (depends on 1)

An aptamer that specifically recognizes the peptide or variant thereof according to claim 1, optionally the peptide or variant thereof is bound to an MHC molecule.

### Claim 12 (depends on 1)

A nucleic acid, encoding for a peptide or variant thereof according to claim 1, an antibody or fragment thereof, a T-cell receptor or fragment thereof, optionally linked to a heterologous promoter sequence, or an expression vector expressing said nucleic acid.

### Claim 13 (depends on 1)

A recombinant host cell comprising the peptide or variant according to claim 1, an antibody or fragment thereof, a T-cell receptor or fragment thereof or a nucleic acid encoding said peptide or variant or an expression vector expressing said nucleic acid, wherein said host cell optionally is selected from an antigen presenting cell, optionally a dendritic cell, a T cell or an NK cell.

### Claim 14 (depends on 1)

An in vitro method for producing activated T lymphocytes, the method comprising contacting in vitro T cells with antigen loaded human class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said T cells in an antigen specific manner, wherein said antigen is a peptide or variant according to claim 1.

### Claim 15 (depends on 14)

An activated T lymphocyte, produced by the method according to claim 14, that selectively recognizes a cell which presents a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 149, and variant sequences thereof which are at least 88% homologous to SEQ ID No. 1 to SEQ ID No. 149.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising at least one active ingredient selected from the group consisting of the peptide or variant according to claim 1, an antibody or fragment thereof, a T-cell receptor or fragment thereof, an aptamer that specifically recognizes said peptide or variant, a nucleic acid encoding said peptide or variant or an expression vector expressing said nucleic acid, a host cell comprising said peptide or variant, or an activated T lymphocyte that selectively recognizes a cell which presents a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 149, and variant sequences thereof which are at least 88% homologous to SEQ ID No. 1 to SEQ ID No. 149, or a conjugated or labelled active ingredient, and a pharmaceutically acceptable carrier, and optionally, one or more pharmaceutically acceptable excipients and/or stabilizers.

### Claim 17 (depends on 1)

A method for producing the peptide or variant thereof according to claim 1, an antibody or fragment thereof, or a T-cell receptor or fragment thereof, the method comprising culturing a host cell, and isolating the peptide or variant thereof, the antibody or fragment thereof or the T cell receptor or fragment thereof from said host cell and/or culture medium thereof.

### Claim 18 (depends on 1)

The peptide or variant according to claim 1, an antibody or fragment thereof, a T-cell receptor or fragment thereof, an aptamer that specifically recognizes said peptide or variant, a nucleic acid encoding said peptide or variant or an expression vector expressing said nucleic acid, a host cell comprising said peptide or variant, or an activated T lymphocyte that selectively recognizes a cell which presents a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 149, and variant sequences thereof which are at least 88% homologous to SEQ ID No. 1 to SEQ ID No. 149, for use in medicine.

### Claim 19 (depends on 15)

A method for killing target cells in a patient which target cells present a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 149, and variant sequences thereof which are at least 88% homologous to SEQ ID No. 1 to SEQ ID No. 149, the method comprising administering to the patient an effective number of activated T cells as defined in claim 15.

### Claim 20 (depends on 1)

The peptide or variant according to claim 1, an antibody or fragment thereof, a T-cell receptor or fragment thereof, an aptamer that specifically recognizes said peptide or variant, a nucleic acid encoding said peptide or variant or an expression vector expressing said nucleic acid, a host cell comprising said peptide or variant, or an activated T lymphocyte that selectively recognizes a cell which presents a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 149, and variant sequences thereof which are at least 88% homologous to SEQ ID No. 1 to SEQ ID No. 149, for use in diagnosis and/or treatment of cancer, or for use in the manufacture of a medicament against cancer.

### Claim 21 (depends on 20)

The peptide or variant according to claim 20, wherein said cancer is selected from the group of ovarian cancer, hepatocellular carcinoma, colorectal carcinoma, glioblastoma, gastric cancer, esophageal cancer, non-small cell lung cancer, small cell lung cancer, pancreatic cancer, renal cell carcinoma, prostate cancer, melanoma, breast cancer, chronic lymphocytic leukemia, Non-Hodgkin lymphoma, acute myeloid leukemia, gallbladder cancer and cholangiocarcinoma, urinary bladder cancer, uterine cancer, head and neck squamous cell carcinoma, mesothelioma and other tumors that show an overexpression of a protein from which a peptide SEQ ID No. 1 to SEQ ID No. 205 is derived from.

### Claim 22 (depends on 1)

A kit comprising:
a) a container comprising a pharmaceutical composition containing the peptide(s) or the variant according to claim 1, an antibody or fragment thereof, a T-cell receptor or fragment thereof, an aptamer that specifically recognizes said peptide or variant, a nucleic acid encoding said peptide or variant or an expression vector expressing said nucleic acid, a host cell comprising said peptide or variant, or an activated T lymphocyte that selectively recognizes a cell which presents a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 149, and variant sequences thereof which are at least 88% homologous to SEQ ID No. 1 to SEQ ID No. 149, in solution or in lyophilized form;
b) optionally, a second container containing a diluent or reconstituting solution for the lyophilized formulation;
c) optionally, at least one more peptides selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 205, and
d) optionally, instructions for (i) use of the solution or (ii) reconstitution and/or use of the lyophilized formulation.

### Claim 23 (depends on 22)

The kit according to claim 22, further comprising one or more of (iii) a buffer, (iv) a diluent, (v) a filter, (vi) a needle, or (v) a syringe.

### Claim 24

A method for producing a personalized anti-cancer vaccine or a compound-based and/or cellular therapy for an individual patient, said method comprising:
a) identifying tumor-associated peptides (TUMAPs) presented by a tumor sample from said individual patient;
b) comparing the peptides as identified in a) with a warehouse of peptides that have been pre-screened for immunogenicity and/or over-presentation in tumors as compared to normal tissues, wherein said warehouse comprises a plurality of peptides selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 205;
c) selecting at least one peptide from the warehouse that matches a TUMAP identified in the patient; and
d) manufacturing and/or formulating the personalized vaccine or compound-based or cellular therapy based on step c).

### Claim 25 (depends on 24)

The method according to claim 24, wherein said TUMAPs are identified by:
a1) comparing expression data from the tumor sample to expression data from a sample of normal tissue corresponding to the tissue type of the tumor sample to identify proteins that are over-expressed or aberrantly expressed in the tumor sample; and
a2) correlating the expression data with sequences of MHC ligands bound to MHC class I and/or class II molecules in the tumor sample to identify MHC ligands derived from proteins over-expressed or aberrantly expressed by the tumor.

### Claim 26 (depends on 24)

The method according to claim 24, wherein the sequences of MHC ligands are identified by eluting bound peptides from MHC molecules isolated from the tumor sample, and sequencing the eluted ligands.

### Claim 27 (depends on 24)

The method according to claim 24, wherein the normal tissue corresponding to the tissue type of the tumor sample is obtained from the same patient.

### Claim 28 (depends on 24)

The method according to claim 24, wherein the peptides included in the warehouse are identified by:
aa. Performing genome-wide messenger ribonucleic acid (mRNA) expression analysis by one or more highly parallel methods, optionally microarrays or sequencing-based expression profiling, comprising identify genes that over-expressed in a malignant tissue, compared with a normal tissue or tissues;
ab. Selecting peptides encoded by selectively expressed or over-expressed genes as detected in step aa, and
ac. Determining an induction of in vivo T-cell responses by the peptides as selected comprising in vitro immunogenicity assays using human T cells from healthy donors or said patient; or
ba. Identifying HLA ligands from said tumor sample using mass spectrometry;
bb. Performing genome-wide messenger ribonucleic acid (mRNA) expression analysis by one or more highly parallel methods, optionally microarrays or sequencing-based expression profiling, comprising identify genes that over-expressed in a malignant tissue, compared with a normal tissue or tissues;
bc. Comparing the identified HLA ligands to said gene expression data;
bd. Selecting peptides encoded by selectively expressed or over-expressed genes as detected in bc;
be. Re-detecting of selected TUMAPs from step bd on tumor tissue and lack of or infrequent detection on healthy tissues and confirming the relevance of over-expression at the mRNA level; and
bf. Determining an induction of in vivo T-cell responses by the peptides as selected comprising in vitro immunogenicity assays using human T cells from healthy donors or said patient.

### Claim 29 (depends on 24)

The method according to claim 24, wherein the immunogenicity of the peptides included in the warehouse is determined by a method comprising in vitro immunogenicity assays, patient immunomonitoring for individual HLA binding, MHC multimer staining, ELISPOT assays and/or intracellular cytokine staining.

### Claim 30 (depends on 24)

The method according to claim 24, wherein said warehouse comprises a plurality of peptides selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 149.

### Claim 31 (depends on 24)

The method according to claim 24, further comprising identifying at least one mutation that is unique to the tumor sample relative to normal corresponding tissue from the individual patient, and selecting a peptide that correlates with the mutation for inclusion in the vaccine or for the generation of cellular therapies.

### Claim 32 (depends on 31)

The method according to claim 31, wherein said at least one mutation is identified by whole genome sequencing.
